Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation
John P. Clancy(Cystic Fibrosis Foundation), Michael W. Konstan(Roche (Switzerland)), Peter R. Durie(University of Toronto), Scott H. Donaldson(University of North Carolina at Chapel Hill), Inez Bronsveld(University Medical Center Utrecht), Melissa A. Ashlock(Cystic Fibrosis Foundation), Manfred Ballmann(Medizinische Hochschule Hannover), Michael S. Schechter(Emory University), Richard B. Moss(Palo Alto University), Henry L. Dorkin(Boston Children's Hospital), G Spencer-Green(Vertex Pharmaceuticals (United States)), Manu Jain(Northwestern University), Karl Yen(Vertex Pharmaceuticals (United States)), Preston W. Campbell(Cystic Fibrosis Foundation), Karen McCoy(Nationwide Children's Hospital), Jordan Dunitz(University of Minnesota System), Steve Wisseh(Vertex Pharmaceuticals (United States)), K. De Boeck(Universitair Ziekenhuis Leuven), Ronald C. Rubenstein(Children's Hospital of Philadelphia), Martyn C. Botfield(Vertex Pharmaceuticals (United States)), Laurent Vernillet(Vertex Pharmaceuticals (United States)), Raouf Amin(Cincinnati Children's Hospital Medical Center), Moira L. Aitken(University of Washington), Michael Boyle(Royal College of Surgeons in Ireland), Claudia L. Ordoñez(Vertex Pharmaceuticals (United States)), Frank J. Accurso(University of Colorado Anschutz Medical Campus), Anissa Leonard(UCLouvain), Steven M. Rowe(University of Alabama at Birmingham), Daniel Rosenbluth(Washington University in St. Louis), Joseph M. Pilewski(University of Pittsburgh)
Cited by 496
Related Papers
Update on Key Emerging Challenges in Cystic Fibrosis
|Medical Principles and Practice|2014|3.7k
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k